We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Age Alters Diagnostic Performance of Cardiac Troponin

By LabMedica International staff writers
Posted on 20 Sep 2022
Print article
Image: High-sensitivity cardiac troponin I: relying on the sex-specific 99th percentile upper reference limit of cardiac troponin may incorrectly suggest myocardial infarction (MI) in older adults with suspected heart attacks (Photo courtesy of Blood Tests in London)
Image: High-sensitivity cardiac troponin I: relying on the sex-specific 99th percentile upper reference limit of cardiac troponin may incorrectly suggest myocardial infarction (MI) in older adults with suspected heart attacks (Photo courtesy of Blood Tests in London)

The guideline-recommended thresholds for increased high-sensitivity cardiac troponin I (hs-cTnI), indicating myocardial injury and potential infarction, performed at a similar sensitivity around 80% in people across age groups.

Relying on the sex-specific 99th percentile upper reference limit of cardiac troponin may incorrectly suggest myocardial infarction (MI) in older adults with suspected heart attacks, though no diagnostic approach has emerged as a better alternative.

Cardiovascular Scientists at the University of Edinburgh (Edinburgh, UK) and their colleagues assessed the diagnostic accuracy of high-sensitivity cardiac troponin I at presentation for the diagnosis of type 1, type 2, or type 4b myocardial infarction across three age groups (<50, 50–74, and ≥75 years) using guideline-recommended sex-specific and age-adjusted 99th centile thresholds. This was a secondary analysis of a multicenter trial across 10 hospitals in Scotland of consecutive patients with suspected myocardial infarction. The study included 46,435 consecutive patients aged 18 to 108 years (mean, 61±17 years), 5,216 (11%) had a diagnosis of myocardial infarction.

The team reported that thresholds for increased high-sensitivity cardiac troponin I (hs-cTnI), indicating myocardial injury and potential infarction, performed at a similar sensitivity around 80% in people across age groups. However, specificity for MI fell with increasing age: 98.3% in people under 50 years, 95.5% in those 50-74, and 82.6% in those age 75 and older. For that oldest group, age-adjusted 99th percentile thresholds improved specificity to 91.3% at the cost of a major loss in sensitivity (down from 81.6% to 55.9%) for an overall positive predictive value (PPV) of 59.3%. Other alternative hs-cTnI analyses they tried for people over 75 years old, applying a universal rule-in threshold of 64 ng/L, and factoring in the person's cardiovascular comorbidities, also failed to take MI diagnosis to an acceptable balance of sensitivity and specificity similar to that seen in younger patients.

Atul Anand, MD, PhD, a cardiovascular scientist and a lead author of the study, said, “No approach achieved parity in the diagnosis between older and younger patients with specificity and PPV reducing with advancing age regardless of the threshold adopted, and alternatives to the guideline-recommended approach resulted in a marked reduction in sensitivity in older persons.”

The authors concluded that age alters the diagnostic performance of cardiac troponin, with reduced specificity and positive predictive value in older patients when applying the guideline-recommended or age-adjusted 99th centiles. Individualized diagnostic approaches rather than the adjustment of binary thresholds are needed in an aging population. The study was published on September 15, 2022 in the journal Circulation.

Related Links:
University of Edinburgh

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.